Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bristol-Myers Squibb will pay Enterome $15 million up front as part of a pact to develop microbiome-derived biomarkers and therapeutics for cancer. The partners will also look for microbiome-derived biomarkers that could indicate whether a patient will benefit from BMS’s immuno-oncology treatments. Given growing evidence that the gut microbiome is involved in how the body responds or grows resistant to cancer immunotherapies, the companies hope to find new targets and therapies that could boost the efficacy of oncology drugs.
This article has been sent to the following recipient: